High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab-Reference-Cited by-同舟云学术

High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab

Published:2015-09-04 Issue:3 Volume:43 Page:489-498
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Weber Tobias,Bötticher Benedikt,Mier Walter,Sauter Max,Krämer Susanne,Leotta Karin,Keller Armin,Schlegelmilch Anne,Grosse-Hovest Ludger,Jäger Dirk,Haberkorn Uwe,Arndt Michaela A. E.,Krauss Jürgen

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-015-3175-6.pdf

Reference48 articles.

1. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91. doi: 10.1016/S1470-2045(06)70664-7 .

2. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26. doi: 10.1200/JCO.2005.09.131 .

3. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027–33. doi: 10.1200/JCO.2005.09.137 .

4. Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in non-Hodgkin’s lymphoma. Acta Oncol. 2003;42(5-6):605–19.

5. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3(6):488–99. doi: 10.1038/nrd1413 .

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma;Exploration of Targeted Anti-tumor Therapy;2024-02-28

2. Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update;Seminars in Nuclear Medicine;2023-05

3. Radiolabeled Antibodies for Cancer Radioimmunotherapy;Nuclear Medicine and Immunology;2021-11-25

4. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu;EJNMMI Radiopharmacy and Chemistry;2020-11-09

5. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma;Journal of Nuclear Medicine;2020-04-03